Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 131

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 131
---
50 per share would be payable upon the first commercial sale in Japan to a third-party customer after regulatory approval for ZURZUVAE for the treatment of major depressive disorder (MDD) in Japan by June 30, 2026. The maximum amount payable with respect to a CVR issued in respect to each Share is $3.50, an aggregate of approximately $234 million. See Note 3, Sage Acquisition, for the key assumptions used in the valuation of the contingent consideration liability related to the Sage Acquisition.

24

Change in the Fair Value of Contingent ConsiderationThe following tables provide a reconciliation of the beginning and ending balances related to the contingent consideration liability for the USWM Acquisition, Adamas Acquisition, and Sage Acquisition (dollars in thousands):USWM AcquisitionAdamas AcquisitionSage AcquisitionTotalBalance at December 31, 2024$47,340 $— $— $47,340 Contingent consideration from Sage Acquisition— — 11,448 11,448 Change in fair value recognized in earnings7,660 — — 7,660 Milestone payments through June 30, 2025(27,295)— — (27,295)Reclassification to Other Current Liabilities(27,705)— (27,705)Balance at September 30, 2025 (unaudited)$— $— $11,448 $11,448 As aforementioned, the remaining liability as of June 30, 2025 for the contingent consideration related to the USWM Acquisition was reclassified to Other Current Liabilities in the second quarter of 2025. Thereafter, the Company made an additional milestone payment of  $1.9 million in the third quarter of 2025. USWM AcquisitionAdamas AcquisitionTotalBalance at December 31, 2023$46,400 $7,050 $53,450 Change in fair value recognized in earnings130 (6,596)(6,466)Balance at September 30, 2024 (unaudited)$46,530 $454 $46,984 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•The Company recorded a $7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the nine months ended September 30, 2025. No expense was recorded during the